A Phase 1/2 interventional study of Biospecimen Collection and Bone Marrow Aspiration and Biopsy in Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 194th largest by enrollment, is one of 31 that started in 2022, is one of 28 in phase 1/2, reaches primary completion later than 18 of the 144 other live ones, and was the 62nd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
203 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 27 · Phase 4 5
First in 2010; this study’s year is marked. 31 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 58 across the 203 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 203 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
154 studies in Leukemia, Myeloid, Acute by National Cancer Institute (NCI): 21 open now, 41 under way, 1 of them phase 3. Of 107 finished, 39 (36%) have results posted.
Among the 154 studies in Leukemia, Myeloid, Acute by National Cancer Institute (NCI), this one is the 138th largest by enrollment of the 144 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 in phase 1/2, reaches primary completion later than 12 of the 39 other live ones, and was the 131st registered.
National Cancer Institute (NCI)’s Leukemia, Myeloid, Acute studies by the year they started, since 1996.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
Among National Cancer Institute (NCI)’s 154 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called fms-like tyrosine kinase 3 (FLT3). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is an enzyme inhibitor. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Venetoclax and decitabine are commonly given together for older patients with AML ASTX727 (a pill form of decitabine + cedazuridine) has been found to be equal to decitabine (given intravenously), and this part of the study is to confirm that venetoclax and ASTX727 is as safe as venetoclax and decitabine given intravenously. This study allows for lowering doses of study drugs to assure the dose chosen for the randomized study (second portion of this trial) is safe and tolerable for people. Giving ASTX727 in combination with venetoclax may help in the treatment of patients with higher-risk acute myeloid leukemia.
PRIMARY OBJECTIVES:
I. To determine and compare the preliminary efficacy of venetoclax +ASTX727 versus (vs.) standard anthracycline induction therapy ('7+3') with a primary endpoint of event-free survival (EFS).
SECONDARY OBJECTIVES:
I. To determine the complete response (complete response [CR] + complete response with incomplete bone marrow recovery [CRi]) rate in patients with treatment naive FLT3 wild type (WT) acute myeloid leukemia (AML) treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
II. To determine the duration of response (DoR) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
III. To determine the progression free survival (PFS) of patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
IV. To determine the overall response rate (ORR) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
V. To determine the overall survival (OS) of patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
VI. To determine the proportion of patients receiving stem cell transplantation (SCT) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').
VII. To identify mutational burdens in venetoclax +ASTX727 sensitive vs. resistant AML leukemia initiating cells (LICs).
EXPLORATORY OBJECTIVES:
I. To identify transcriptomic signatures in venetoclax +ASTX727 sensitive vs. resistant AML LICs.
II. Determine the utility of high-throughput phenotype-based assessment of drug efficacy for predicting patient response to venetoclax +ASTX727.
III. Determine if treatment failure is a function of therapy sequence or results in resistance to the alternative therapy by conducting a co-clinical trial via patient-derived xenograft (PDX).
IV. To characterize the pharmacokinetics of venetoclax. V. To determine the morphologic leukemia-free state (MLFS) rate in patients with treatment naïve FLT3WT AML treated with venetoclax and ASTX727 vs. 7+3 therapy.
OUTLINE: This is a phase Ib dose de-escalation study followed by a phase II randomized study.
PHASE Ib: Patients receive ASTX727 (decitabine and cedazuridine) orally (PO) once daily (QD) on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
ARM II: Patients receive cytarabine intravenously (IV) over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.
After completion of study treatment, patients are followed up every 3 months for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Decitabine and Cedazuridine · Drug: Venetoclax
Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.
Procedure: Bone Marrow Aspiration and Biopsy · Drug: Cytarabine · Drug: Daunorubicin
Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Decitabine and Cedazuridine · Drug: Venetoclax
Undergo collection of blood samples
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo bone marrow aspiration and biopsy
Given IV
Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453
Given IV
Also known as: Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C
Given PO
Also known as: ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi
Given PO
Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
Recommended Safe Phase 2 Dose (RP2D) of Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax (Phase Ib)
The highest dose level in which at most 1 patient in 6 experiences dose-limiting toxicity (DLT).
Time frame: From start of treatment to end of first cycle (28 days)
Incidence of Adverse Events (Phase Ib)
Will be tabulated and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Summary statistics will be provided for all adverse events reported. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percent and frequencies for categorical parameters, will be presented
Time frame: Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.
Event-free Survival (EFS) (Phase II)
Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. EFS is defined as survival without death, blasts\>20%, myeloid sarcoma, or AML in the central nervous system (CNS disease).
Time frame: Up to 2 years after completion of study treatment
Complete Response Rate (Phase II)
Rate of complete response (CR) + complete response with incomplete bone marrow recovery (CRi). The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery.
Time frame: Up to 2 years after completion of study treatment
Duration of Response (Phase II)
Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.
Time frame: Up to 2 years after completion of study treatment
Progression-free Survival (PFS) (Phase II)
The distribution of PFS will be estimated using the method of Kaplan and Meier. Hazard rate for PFS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.
Time frame: Time from randomization date to the date of progression or death for any reason, assessed up to 2 years after completion of study treatment
Overall Response Rate (Phase II)
Rate of partial response (PR) + CRi + CR in patients with treatment naive AML treated with venetoclax and ASTX727. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.
Time frame: Up to 2 years after completion of study treatment
Overall Survival (OS) (Phase II)
The distribution of OS will be estimated using the method of Kaplan and Meier. Hazard rate for OS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.
Time frame: Time from randomization to death for any reason, assessed up to 2 years after completion of study treatment
The Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II)
Time frame: Up to 2 years after completion of study treatment
Mutational Burdens in Venetoclax + ASTX727 Sensitive vs. Resistant AML Leukemia Initiating Cells (LICs) (Phase II)
Time frame: Up to 2 years after completion of study treatment
| Milestone | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) |
|---|---|---|---|
| Started | 2 | 2 | 1 |
| Completed | 0 | 0 | 1 |
| Not completed | 2 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Starting consolidation therapy off study | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
The highest dose level in which at most 1 patient in 6 experiences dose-limiting toxicity (DLT).
No measurements were reported for this outcome.
Will be tabulated and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Summary statistics will be provided for all adverse events reported. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percent and frequencies for categorical parameters, will be presented
| Participants | Phase Ib (Decitabine and Cedazuridine, Venetoclax) |
|---|---|
| Bacteremia — Grade 1 | 0 |
| Bacteremia — Grade 2 | 1 |
| Bacteremia — Grade 3 | 0 |
| Bacteremia — Grade 4 | 0 |
| Bacteremia — Grade 5 | 0 |
| Constipation — Grade 1 | 1 |
| Constipation — Grade 2 | 0 |
| Constipation — Grade 3 | 0 |
| Constipation — Grade 4 | 0 |
| Constipation — Grade 5 | 0 |
| Fatigue — Grade 1 | 1 |
| Fatigue — Grade 2 | 0 |
| Fatigue — Grade 3 | 0 |
| Fatigue — Grade 4 | 0 |
| Fatigue — Grade 5 | 0 |
| Hyperkalemia — Grade 1 | 0 |
| Hyperkalemia — Grade 2 | 1 |
| Hyperkalemia — Grade 3 | 0 |
| Hyperkalemia — Grade 4 | 0 |
| Hyperkalemia — Grade 5 | 0 |
| Hyperuricemia — Grade 1 | 1 |
| Hyperuricemia — Grade 2 | 0 |
| Hyperuricemia — Grade 3 | 0 |
| Hyperuricemia — Grade 4 | 0 |
| Hyperuricemia — Grade 5 | 0 |
| Lymphocyte count decreased — Grade 1 | 0 |
| Lymphocyte count decreased — Grade 2 | 0 |
| Lymphocyte count decreased — Grade 3 | 1 |
| Lymphocyte count decreased — Grade 4 | 0 |
| Lymphocyte count decreased — Grade 5 | 0 |
| Nausea — Grade 1 | 1 |
| Nausea — Grade 2 | 0 |
| Nausea — Grade 3 | 0 |
| Nausea — Grade 4 | 0 |
| Nausea — Grade 5 | 0 |
| Platelets count decreased — Grade 1 | 1 |
| Platelets count decreased — Grade 2 | 0 |
| Platelets count decreased — Grade 3 | 0 |
| Platelets count decreased — Grade 4 | 0 |
| Platelets count decreased — Grade 5 | 0 |
| White blood cell decreased — Grade 1 | 0 |
| White blood cell decreased — Grade 2 | 0 |
| White blood cell decreased — Grade 3 | 0 |
| White blood cell decreased — Grade 4 | 1 |
| White blood cell decreased — Grade 5 | 0 |
Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. EFS is defined as survival without death, blasts\>20%, myeloid sarcoma, or AML in the central nervous system (CNS disease).
| days | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Event-free Survival (EFS) (Phase II) | 64 (15 to 113) | NA (0 to 816) |
Rate of complete response (CR) + complete response with incomplete bone marrow recovery (CRi). The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery.
| Participants | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Complete Response Rate (Phase II) | 1 | 1 |
Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.
| days | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Duration of Response (Phase II) | 113 | 821 |
The distribution of PFS will be estimated using the method of Kaplan and Meier. Hazard rate for PFS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.
| days | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Progression-free Survival (PFS) (Phase II) | 64 (15 to 113) | 64 (0 to 816) |
Rate of partial response (PR) + CRi + CR in patients with treatment naive AML treated with venetoclax and ASTX727. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.
| Participants | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Overall Response Rate (Phase II) | 1 | 1 |
The distribution of OS will be estimated using the method of Kaplan and Meier. Hazard rate for OS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.
| days | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| Overall Survival (OS) (Phase II) | 64 (15 to 113) | NA (0 to 816) |
| Participants | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) |
|---|---|---|
| The Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II) | 0 | 0 |
No measurements were reported for this outcome.
Collected over Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Decitabine and Cedazuridine, Venetoclax) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Arm II (Cytarabine, Daunorubicin) | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Phase Ib (Decitabine and Cedazuridine, Venetoclax) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/2 | 0/2 | 1/1 |
| BacteremiaInfections and infestations | 0/2 | 0/2 | 1/1 |
| Enterobacter septicemiaInfections and infestations | 0/2 | 0/2 | 1/1 |
| Failure to thriveInvestigations | 0/2 | 0/2 | 1/1 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/2 | 0/2 | 1/1 |
| LethargyNervous system disorders | 0/2 | 0/2 | 1/1 |
| ConfusionPsychiatric disorders | 1/2 | 0/2 | 0/1 |
| Lung InfectionRespiratory, thoracic and mediastinal disorders | 0/2 | 1/2 | 0/1 |
| Spleen painGeneral disorders | 1/2 | 0/2 | 0/1 |
| Suspected disease progressionGeneral disorders | 1/2 | 0/2 | 0/1 |
| Event | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 1/2 | 0/2 | 1/1 |
| AnorexiaMetabolism and nutrition disorders | 1/2 | 1/2 | 1/1 |
| Back painMusculoskeletal and connective tissue disorders | 1/2 | 0/2 | 1/1 |
| ChillsGeneral disorders | 0/2 | 0/2 | 1/1 |
| ConfusionPsychiatric disorders | 0/2 | 0/2 | 1/1 |
| ConstipationGastrointestinal disorders | 2/2 | 0/2 | 1/1 |
| Creatinine increasedInvestigations | 1/2 | 0/2 | 1/1 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/2 | 1/2 | 1/1 |
| FatigueGeneral disorders | 2/2 | 0/2 | 1/1 |
| Generalized body painGeneral disorders | 0/2 | 0/2 | 1/1 |
| Age, Categorical(Participants) | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 1 | 4 |
| >=65 years | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 |
| Male | 1 | 1 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 2 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 1 | 5 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm I (Decitabine and Cedazuridine, Venetoclax) | Arm II (Cytarabine, Daunorubicin) | Phase Ib (Decitabine and Cedazuridine, Venetoclax) | Total |
|---|---|---|---|---|
| United States | 2 | 2 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Ran from Feb 2022 to primary completion in Jun 2025, 39 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's 39 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
National Cancer Institute (NCI) →